Guangping Lu

471 total citations
22 papers, 350 citations indexed

About

Guangping Lu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Guangping Lu has authored 22 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Guangping Lu's work include Chemotherapy-induced cardiotoxicity and mitigation (5 papers), MicroRNA in disease regulation (4 papers) and Genomics, phytochemicals, and oxidative stress (3 papers). Guangping Lu is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (5 papers), MicroRNA in disease regulation (4 papers) and Genomics, phytochemicals, and oxidative stress (3 papers). Guangping Lu collaborates with scholars based in China and United States. Guangping Lu's co-authors include Junlian Gu, Yufeng Tang, Yuanfang Guo, Mengjie Xiao, Qingbo Liu, Jiahao Li, Jingjing Zhang, Jie Wang, Ting Gao and Jiahui Chu and has published in prestigious journals such as Nutrients, Antioxidants and Redox Signaling and Advanced Science.

In The Last Decade

Guangping Lu

21 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guangping Lu China 11 211 92 72 62 35 22 350
Huiting Zhong China 6 182 0.9× 80 0.9× 52 0.7× 46 0.7× 19 0.5× 11 279
Shengyu Cui China 13 261 1.2× 126 1.4× 37 0.5× 49 0.8× 21 0.6× 31 407
Shenghui Sun China 9 215 1.0× 109 1.2× 56 0.8× 114 1.8× 102 2.9× 13 437
Kang Du China 11 188 0.9× 132 1.4× 34 0.5× 100 1.6× 76 2.2× 22 407
Yun-Ching Chang Taiwan 9 206 1.0× 84 0.9× 56 0.8× 37 0.6× 16 0.5× 14 358
Michihiro Sakai Japan 9 290 1.4× 50 0.5× 53 0.7× 30 0.5× 31 0.9× 20 488
Krisztián Erős Hungary 10 170 0.8× 24 0.3× 94 1.3× 63 1.0× 21 0.6× 14 327
Soo Hyuk Kim South Korea 11 171 0.8× 92 1.0× 46 0.6× 84 1.4× 27 0.8× 14 388
Mathieu Cinato France 10 113 0.5× 67 0.7× 34 0.5× 54 0.9× 44 1.3× 15 319

Countries citing papers authored by Guangping Lu

Since Specialization
Citations

This map shows the geographic impact of Guangping Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangping Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangping Lu more than expected).

Fields of papers citing papers by Guangping Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangping Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangping Lu. The network helps show where Guangping Lu may publish in the future.

Co-authorship network of co-authors of Guangping Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Guangping Lu. A scholar is included among the top collaborators of Guangping Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangping Lu. Guangping Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guo, Yuanfang, Jie Wang, Dongmei Zhang, et al.. (2025). Diabetes-associated sleep fragmentation impairs liver and heart function via SIRT1-dependent epigenetic modulation of NADPH oxidase 4. Acta Pharmaceutica Sinica B. 15(3). 1480–1496. 1 indexed citations
2.
Zhang, Xiaohui, Xinyu Tang, Ting Gao, et al.. (2025). Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1. Acta Pharmaceutica Sinica B. 15(7). 3591–3610.
3.
Gao, Ting, Yufeng Tang, Tao Zeng, et al.. (2025). Neuraminidase 1 Exacerbated Glycolytic Dysregulation and Cardiotoxicity by Destabilizing SIRT1 through Interactions with NRF2 and HIF1α. Advanced Science. 12(25). e2414504–e2414504. 1 indexed citations
4.
Lu, Guangping, Yufeng Tang, Ou Chen, et al.. (2024). Aberrant activation of p53-TRIB3 axis contributes to diabetic myocardial insulin resistance and sulforaphane protection. Journal of Advanced Research. 72. 467–484. 1 indexed citations
5.
Li, Jiahao, Yufeng Tang, Guangping Lu, et al.. (2024). Elevation of p53 sensitizes obese kidney to adriamycin-induced aberrant lipid homeostasis via repressing HNF4α-mediated FGF21 sensitivity. Journal of Advanced Research. 72. 165–180. 1 indexed citations
6.
Lu, Guangping, Jiahao Li, Ting Gao, et al.. (2023). Integration of dietary nutrition and TRIB3 action into diabetes mellitus. Nutrition Reviews. 82(3). 361–373. 5 indexed citations
7.
Guo, Yuanfang, Yufeng Tang, Guangping Lu, & Junlian Gu. (2023). p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act. Nutrients. 15(10). 2259–2259. 15 indexed citations
8.
Gao, Ting, Jie Wang, Mengjie Xiao, et al.. (2023). SESN2-Mediated AKT/GSK-3β/NRF2 Activation to Ameliorate Adriamycin Cardiotoxicity in High-Fat Diet–Induced Obese Mice. Antioxidants and Redox Signaling. 40(10-12). 598–615. 5 indexed citations
9.
Liu, Qingbo, Jiahao Li, Mengjie Xiao, et al.. (2022). Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway. Frontiers in Pharmacology. 13. 940406–940406. 17 indexed citations
10.
Wang, Jie, Yufeng Tang, Jingjing Zhang, et al.. (2022). Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2. Redox Biology. 52. 102310–102310. 81 indexed citations
11.
Wang, Jie, Xiaohui Zhang, Jie Wang, et al.. (2022). Resveratrol Attenuates High Glucose-Induced Osteoblast Dysfunction via AKT/GSK3β/FYN-Mediated NRF2 Activation. Frontiers in Pharmacology. 13. 862618–862618. 22 indexed citations
12.
Xiao, Mengjie, Yufeng Tang, Guangping Lu, et al.. (2021). Regulatory role of endogenous and exogenous fibroblast growth factor 1 in the cardiovascular system and related diseases. Pharmacological Research. 169. 105596–105596. 6 indexed citations
13.
Xiao, Mengjie, Yufeng Tang, Jie Wang, et al.. (2021). A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity. Redox Biology. 49. 102219–102219. 24 indexed citations
14.
Lou, Li‐Li, et al.. (2020). MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer. Journal of Experimental & Clinical Cancer Research. 39(1). 143–143. 22 indexed citations
15.
Liu, Jinwei, Zhi‐Xia Yang, Xiaolan Zhang, et al.. (2020). PNMA5 knockdown suppresses the proliferation, invasion, and metastasis of epithelial ovarian cancer cells. Translational Cancer Research. 9(5). 3691–3702. 1 indexed citations
16.
Lu, Guangping, Jinjin Zhang, Xiangyong Liu, et al.. (2019). Regulatory network of two circRNAs and an miRNA with their targeted genes under astilbin treatment in pulmonary fibrosis. Journal of Cellular and Molecular Medicine. 23(10). 6720–6729. 22 indexed citations
17.
Chu, Jiahui, Yongfei Li, Xuemei Fan, et al.. (2018). MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells. Cellular Physiology and Biochemistry. 48(2). 593–604. 39 indexed citations
18.
Lu, Guangping, Jun Li, Jiahui Chu, et al.. (2017). 1,25(OH)2D3 deficiency increases TM40D tumor growth in bone and accelerates tumor-induced bone destruction in a breast cancer bone metastasis model. Biomedicine & Pharmacotherapy. 95. 1033–1039. 9 indexed citations
19.
Lu, Xiangdong, Jingjing Ma, Jiahui Chu, et al.. (2017). MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6. Cellular Physiology and Biochemistry. 44(6). 2346–2356. 30 indexed citations
20.
Lu, Guangping, et al.. (2015). [Efficacy analysis of sequential surgery after the DCF scheme induction chemotherapy in T2-3 laryngeal carcinoma and hypopharyngeal carcinoma].. PubMed. 29(7). 585–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Huiting Zhong Breakdown of academic impact, for papers by Shengyu Cui Breakdown of academic impact, for papers by Shenghui Sun Breakdown of academic impact, for papers by Kang Du Breakdown of academic impact, for papers by Yun-Ching Chang Breakdown of academic impact, for papers by Michihiro Sakai Breakdown of academic impact, for papers by Krisztián Erős Breakdown of academic impact, for papers by Soo Hyuk Kim Breakdown of academic impact, for papers by Mathieu Cinato
Rankless by CCL
2026